{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:05:12Z","timestamp":1751886312290},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12325-010-0097-3","type":"journal-article","created":{"date-parts":[[2011,3,23]],"date-time":"2011-03-23T01:03:11Z","timestamp":1300842191000},"page":"10-15","source":"Crossref","is-referenced-by-count":2,"title":["Azacytidine for the treatment of myelodysplastic syndromes in the elderly"],"prefix":"10.1007","volume":"28","author":[{"given":"Maria Diez","family":"Campelo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina Garcia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina Godoy","family":"Molias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus Feliu","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,9]]},"reference":[{"key":"97_CR1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.295.7.801","volume":"295","author":"J.S. Lee","year":"2006","unstructured":"Lee JS, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801\u2013808.","journal-title":"JAMA"},{"key":"97_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"J.M. Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189\u2013199.","journal-title":"Br J Haematol"},{"key":"97_CR3","unstructured":"The International Agency for Research on Cancer. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon: IARC Press; 2008."},{"key":"97_CR4","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P. Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u20132088.","journal-title":"Blood"},{"key":"97_CR5","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","volume":"25","author":"L. Malcovati","year":"2007","unstructured":"Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503\u20133510.","journal-title":"J Clin Oncol"},{"key":"97_CR6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0609.2008.01124.x","volume":"81","author":"M.J. Park","year":"2008","unstructured":"Park MJ, Kim HJ, Kim SH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008;81:364\u2013373.","journal-title":"Eur J Haematol"},{"key":"97_CR7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","volume":"87","author":"D. Hasse","year":"2008","unstructured":"Hasse D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87:515\u2013526.","journal-title":"Ann Hematol"},{"key":"97_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A. List","year":"2006","unstructured":"List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456\u20131465.","journal-title":"N Engl J Med"},{"key":"97_CR9","first-page":"1997","volume":"100","author":"J. Sierra","year":"2002","unstructured":"Sierra J, P\u00e9rez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997\u20132004.","journal-title":"Blood"},{"key":"97_CR10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1992.tb06430.x","volume":"82","author":"C. Aul","year":"1992","unstructured":"Aul C, Gatterman N, Schneider W. Age related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358\u2013367.","journal-title":"Br J Haematol"},{"key":"97_CR11","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"L.R. Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukaemia group B. J Clin Oncol. 2002;20:2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"97_CR12","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","volume":"113","author":"H. Kantarijan","year":"2008","unstructured":"Kantarijan H, O\u2019Brien S, Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351\u20131361.","journal-title":"Cancer"},{"key":"97_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"M.M. Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649\u2013655.","journal-title":"Am J Clin Oncol"},{"key":"97_CR14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P. Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u2013232.","journal-title":"Lancet Oncol"},{"key":"97_CR15","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2010.04.005","volume":"76","author":"J.F. Seymour","year":"2010","unstructured":"Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (\u226575 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol. 2010;76:218\u2013227.","journal-title":"Crit Rev Oncol"},{"key":"97_CR16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","volume":"85","author":"V. Santini","year":"2010","unstructured":"Santini V, Fenaux P, Mufti GJ. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacytidine. Eur J Haematol. 2010;85:130\u2013138.","journal-title":"Eur J Haematol"},{"key":"97_CR17","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"L.R. Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895\u20133903.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0097-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0097-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0097-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T10:38:55Z","timestamp":1712313535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0097-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":17,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0097-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}